MarketCapExport financials
So-Young International (SY)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
So-Young International Financial Ratios 2025-2011 | SY
Brief overview of So-Young International 's valuation and returns
The review covers five available annual periods spanning 2017 to 2023.
The valuation comparison uses P/E 4.56x (median 4.08x), P/S 0.14x (median 0.08x), P/B 0.13x (median 0.04x). Multiples are on average 80.1% above their own medians. A substantial share of positive expectations may already be priced in.
Current earnings relative to valuation equal about 21.9% on the 1/P/E measure. This is a valuation reference, not an expected payout.
Current measures of operating quality are ROE -15.6%, ROA -9.1%, ROCE -16.4%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.
Valuation takeaway
So-Young International 's market premium is not yet supported by strong capital returns, raising valuation risk.
Annual Financial Ratios So-Young International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.9 | -0.1 | 4.6 | -1.5 | -23.4 | 163.9 | 4.1 | 0.5 | 1.9 | - | - | - | - | - | - | |
P/S |
0.1 | 0.0 | 0.1 | 0.1 | -128.8 | 0.7 | 0.6 | 0.0 | 0.1 | - | - | - | - | - | - |
EV (Enterprise Value) |
774 M | 252 M | 324 M | -4.39 M | 1.01 B | 497 M | 424 M | -232 M | 327 M | - | - | - | - | - | - |
EBITDA per Share |
-2.94 | -7.29 | -0.19 | -0.67 | -0.03 | -0.52 | 2.55 | 2.07 | 0.94 | - | - | - | - | - | - |
EV/EBITDA |
-3.4 | -0.4 | -21.7 | 0.1 | -65.6 | 9.1 | -0.6 | - | - | - | - | - | - | - | - |
PEG |
-0.0 | -0.0 | 0.01 | -0.0 | - | -8.62 | 0.1 | - | - | - | - | - | - | - | - |
P/B |
0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.4 | 0.3 | 0.0 | -0.2 | - | - | - | - | - | - |
P/CF |
-2.0 | -2.5 | 4.3 | -0.9 | 2.3 | 5.3 | 1.9 | 0.1 | 0.4 | - | - | - | - | - | - |
ROE % |
-15.60 | -32.05 | 0.87 | -2.62 | -0.33 | 0.22 | 6.69 | -15.40 | -10.30 | - | - | - | - | - | - |
ROA % |
-9.14 | -21.55 | 0.66 | -2.05 | -0.25 | 0.18 | 5.47 | 4.11 | 3.03 | - | - | - | - | - | - |
ROCE % |
-16.35 | -31.46 | -2.39 | -4.03 | -1.24 | -2.10 | 5.25 | -13.74 | 5.79 | - | - | - | - | - | - |
Current Ratio |
2.7 | 3.5 | 4.9 | 5.4 | 4.1 | 4.9 | 5.5 | 4.4 | 0.8 | - | - | - | - | - | - |
DSO |
18.0 | 19.4 | 11.4 | 5.2 | -6339.7 | 11.1 | 4.1 | - | - | - | - | - | - | - | - |
DIO |
88.3 | 87.0 | 80.3 | 98.5 | 51.1 | - | - | - | - | - | - | - | - | - | - |
DPO |
10.8 | 9.9 | 8.0 | 6.1 | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
106.3 | 106.4 | 91.6 | 103.7 | -6288.6 | 11.1 | 4.1 | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
95.5 | 96.5 | 83.7 | 97.6 | -6288.6 | 11.1 | 4.1 | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in CNY currency
Quarterly Financial Ratios So-Young International
| 2025-Q4 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EBITDA per Share |
-2.94 | -7.29 | -0.19 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-15.60 | -32.05 | 0.87 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-9.14 | -21.55 | 0.66 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-16.35 | -31.46 | -2.39 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
2.7 | 3.5 | 4.9 | - | - | - | - | 4.1 | - | - | - | 4.9 | - | - | - | 5.5 | - | - | - | 4.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
4.5 | 4.8 | 1.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
22.1 | 21.8 | 10.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
2.7 | 2.5 | 0.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in CNY currency
Multiples are an important financial analysis tool for the company So-Young International , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
OptimizeRx Corporation
OPRX
|
$ 8.85 | -5.35 % | $ 164 M |  USA |
 |
American Well Corporation
AMWL
|
$ 12.34 | 2.66 % | $ 198 M | USA |
 |
Evolent Health
EVH
|
$ 4.96 | 2.09 % | $ 566 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.61 | 1.98 % | $ 1.29 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.45 | 0.35 % | $ 101 M | USA |
 |
HealthEquity
HQY
|
$ 102.96 | -0.56 % | $ 8.87 B | USA |
 |
Omnicell
OMCL
|
$ 35.73 | -0.47 % | $ 1.64 B | USA |
 |
Progyny
PGNY
|
$ 36.47 | 0.11 % | $ 3.11 B | USA |
 |
Schrödinger
SDGR
|
$ 31.63 | -2.41 % | $ 2.32 B | USA |
 |
Teladoc Health
TDOC
|
$ 8.96 | 0.17 % | $ 1.58 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Phreesia
PHR
|
$ 12.83 | -2.28 % | $ 766 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
10x Genomics
TXG
|
$ 62.02 | -1.4 % | $ 7.74 B | USA |
 |
Veeva Systems
VEEV
|
$ 305.03 | -0.17 % | $ 49.9 B | USA |
 |
HealthStream
HSTM
|
$ 28.91 | 0.42 % | $ 868 M | USA |
 |
SCWorx Corp.
WORX
|
$ 1.31 | -2.21 % | $ 9.53 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.97 | 0.86 % | $ 3.32 M |  China |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |